Energy Regulation Mechanism and Therapeutic Potential of Asprosin
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Genetic studies of patients with neonatal progeroid syndrome led to the discovery of the novel fasting-induced, glucogenic, and orexigenic hormone named asprosin, the C-terminal cleavage product of profibrillin. Upon secretion, asprosin travels to the liver, where it exerts a glucogenic effect through OR4M1, an olfactory G-protein–coupled receptor. It also crosses the blood-brain barrier to stimulate appetite-modulating neurons in the arcuate nucleus of the hypothalamus, exerting an orexigenic effect via an as yet unidentified receptor. Specifically, it stimulates appetite by activating orexigenic AgRP neurons and inhibiting anorexigenic POMC neurons. Studies have also focused on the therapeutic potential of inhibiting asprosin for treatment of obesity and type 2 diabetes, both of which are characterized by high levels of circulating asprosin. It has been shown that anti-asprosin monoclonal antibodies reduce blood glucose, appetite, and body weight, validating asprosin as a therapeutic target. Current work aims to uncover key features of the asprosin biology such as the identification of its neuronal receptor, identification of the secretion mechanism from adipose tissue, and development of anti-asprosin monoclonal antibodies as diabetes and obesity therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Anti-asprosin monoclonal antibodies reduce blood glucose, appetite, and body weight [183].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [183]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443 · cited 1×
“Interestingly, it took several hours after injection before the increase in food intake occurred, differentiating asprosin from the acutely acting hormone ghrelin (26).”
BackgroundThe role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442 · cited 1×
“Leptin, an anorexigenic hormone secreted from white adipose tissue, also regulates energy balance through modulation of AgRP and POMC neurons (27).”
BackgroundMechanisms of insulin resistance in obesity
Ye, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0262-6 · Cited by 699 · cited 1×
“Additionally, the vast majority of patients with obesity also manifest with insulin resistance (35).”
BackgroundAsprosin, a Fasting-Induced Glucogenic Protein Hormone
Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., Saha, P. K., Del Solar, M., Zhu, B., York, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.063 · Cited by 591 · cited 10×
“While FBN1 is expressed in many tissues, its highest expression in both humans and mice is inwhite adipose (1).”
BackgroundSelf-citationAsprosin is a centrally acting orexigenic hormone
Duerrschmid, C., He, Y., Wang, C., Li, C., Bournat, J. C., Romere, C., Saha, P. K., Lee, M. E., Phillips, K. J., Jain, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4432 · Cited by 357 · cited 10×
“Fbn1 mice were created using CRISPR/ Cas9 to induce a frame shift leading to the deletion of the asprosin-coding region (9).”
BackgroundMethodSelf-citationCell type-specific transcriptomics of hypothalamic energy-sensing neuron responses to weight-loss
Henry, F. E., Sugino, K., Tozer, A., Branco, T., & Sternson, S. M. (2015) · eLife · doi:10.7554/elife.09800 · Cited by 240 · cited 1×
“Comprehensive gene expression profiles did not show Olfr734 expression in AgRP or POMC neurons in mice in either the fasted or fed state (25).”
BackgroundOLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin
Li, E., Shan, H., Chen, L., Long, A., Zhang, Y., Liu, Y., Jia, L., Wei, F., Han, J., Li, T., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.022 · Cited by 221 · cited 20×
“They also had reduced cAMP levels, decreased hepatic glucose release, and improved insulin sensitivity (as measured by insulin tolerance test, hyperinsulimic-euglycemic clamp, and glucose tolerance test) compared with wild-type mice (22).”
BackgroundMethodResultInfluentialWang, Y., Qu, H., Xiong, X., Qiu, Y., Liao, Y., Chen, Y., Zheng, Y., & Zheng, H. (2018) · Mediators of Inflammation · doi:10.1155/2018/9471583 · Cited by 189 · cited 3×
“The authors also showed that plasma asprosin concentration is positively correlated with patient waist circumference, fasting plasma glucose, HbA1c, triglycerides, impaired glucose regulation, type 2 diabetes, and HOMA for insulin resistance (19).”
BackgroundInfluentialLee, T., Yun, S., Jeong, J. H., & Jung, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.03.001 · Cited by 188 · cited 1×
“(16) found that MIN6 pancreatic b-cells and human primary islets containing b-cells secrete asprosin and that secretion is induced by palmitate in a dosedependent manner.”
BackgroundZhang, L., Chen, C., Zhou, N., Fu, Y., & Cheng, X. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.10.034 · Cited by 182 · cited 3×
“While serum asprosin was positively associated with adiposity-related parameters such as BMI, waist circumference, and waist-to-hip ratio in patients with type 2 diabetes, these adiposity markers were not independently associated with asprosin concentrations (18).”
BackgroundInfluential
Cited by
Mazur-Biały, A. I. (2021) · Nutrients · doi:10.3390/nu13020620 · Cited by 97
“Olfr734 is a mouse ortholog of human OR4M1 r ceptor [8].”
BackgroundInfluentialBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Discovery of a possible role of asprosin in ovarian follicular function
Maylem, E. R. S., SPICER, L. J., Batalha, I. M., & Schütz, L. F. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0218 · Cited by 51
A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes
Nam, H., Hong, S., Jung, K. H., Kang, S., Park, M. S., Kang, S., Kim, H. S., Mai, V.-H., Kim, J., Lee, H., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab191 · Cited by 38
Metadata
- Authors
- Hoffmann, J. G., Xie, W., & Chopra, A. R.
- Affiliations
- University Hospitals of Cleveland (US)
- Corresponding author
- Chopra, Atul R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 559-566
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085243
- OpenAlex
- W3011199148
- Cited by
- 52
- References
- 41
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 12 · 2023: 7 · 2022: 11 · 2021: 6 · 2020: 5
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- asprosin, blood-brain barrier, hypothalamic regulation of appetite, arcuate nucleus, AgRP neurons, POMC neurons, obesity, type 2 diabetes, adipose tissue secretion, energy regulation
- MeSH terms
- Fibrillin-1, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Energy Metabolism, Humans, Microfilament Proteins, Obesity, Peptide Fragments, Peptide Hormones, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Energy Regulation Mechanism and Therapeutic Potential of Asprosin. https://app.cochat.ai/papers/10.2337/dbi19-0009
- The paper
- Hoffmann, J. G., Xie, W., & Chopra, A. R. (2020). Energy Regulation Mechanism and Therapeutic Potential of Asprosin. Diabetes. https://doi.org/10.2337/dbi19-0009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.